Can
            <sup>68</sup>
            Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study

Chen, Mengxia; Zhuang, Junlong; Fu, Yao; Guo, Suhan; Zang, Shiming; Ai, Shuyue; Qiu, Xuefeng; Wang, Rui; H, Guo

doi:10.1097/ju.0000000000001481

Cited by 11 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI, for instance, has demonstrated satisfying efficacy in post-treatment residual tumor estimation [ 39 ] with the validation of WMH images. Chen et al [ 40 ] also demonstrated a better performance of 68 Ga-PSMA-11 PET/CT than prostate specific antigen (PSA) response in evaluating pathological response to neoadjuvant therapy using WMH as the reference standard. These studies collectively highlight the potential of WMH in facilitating the assessment following neoadjuvant therapy.…”

Section: Resultsmentioning

confidence: 99%

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

Duan,

Liu,

Wan

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Whole-mount histopathology (WMH) has been a powerful tool to investigate the characteristics of prostate cancer. However, the latest advancement of WMH was yet under summarization. In this review, we offer a comprehensive exposition of current research utilizing WMH in diagnosing and treating prostate cancer (PCa), and summarize the clinical advantages of WMH and outlines potential on future prospects. Methods An extensive PubMed search was conducted until February 26, 2023, with the search term “prostate”, “whole-mount”, “large format histology”, which was limited to the last 4 years. Publications included were restricted to those in English. Other papers were also cited to contribute a better understanding. Results WMH exhibits an enhanced legibility for pathologists, which improved the efficacy of pathologic examination and provide educational value. It simplifies the histopathological registration with medical images, which serves as a convincing reference standard for imaging indicator investigation and medical image-based artificial intelligence (AI). Additionally, WMH provides comprehensive histopathological information for tumor volume estimation, post-treatment evaluation, and provides direct pathological data for AI readers. It also offers complete spatial context for the location estimation of both intraprostatic and extraprostatic cancerous region. Conclusions WMH provides unique benefits in several aspects of clinical diagnosis and treatment of PCa. The utilization of WMH technique facilitates the development and refinement of various clinical technologies. We believe that WMH will play an important role in future clinical applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

Duan,

Liu,

Wan

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Data about radiolabeled PSMA in this setting are sparse and heterogeneous: Chen et al [ 44 ] reported the utility of [ 68 Ga]PSMA-11 PET/CT before and after abiraterone and hormonal therapy as neoadjuvant treatment in patients with advanced hormone-sensitive PCa. They observed that the change in SUVs before and after treatment was significantly associated with the prognosis at univariate analysis.…”

Section: Resultsmentioning

confidence: 99%

PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature

Alongi

Laudicella

Lanzafame

et al. 2022

Cancers

View full text Add to dashboard Cite

The aims of this systematic review were to (1) assess the utility of PSMA-PET and choline-PET in the assessment of response to systemic and local therapy, and to (2) determine the value of both tracers for the prediction of response to therapy and survival outcomes in prostate cancer. We performed a systematic literature search in PubMed/Scopus/Google Scholar/Cochrane/EMBASE databases (between January 2010 and October 2021) accordingly. The quality of the included studies was evaluated following the “Quality Assessment of Prognostic Accuracy Studies” tool (QUAPAS-2). We selected 40 articles: 23 articles discussed the use of PET imaging with [68Ga]PSMA-11 (16 articles/1123 patients) or [11C]/[18F]Choline (7 articles/356 patients) for the prediction of response to radiotherapy (RT) and survival outcomes. Seven articles (three with [68Ga]PSMA-11, three with [11C]Choline, one with [18F]Choline) assessed the role of PET imaging in the evaluation of response to docetaxel (as neoadjuvant therapy in one study, as first-line therapy in five studies, and as a palliative regimen in one study). Seven papers with radiolabeled [18F]Choline PET/CT (n = 121 patients) and three with [68Ga]PSMA-11 PET (n = 87 patients) were selected before and after enzalutamide/abiraterone acetate. Finally, [18F]Choline and [68Ga]PSMA-11 PET/CT as gatekeepers for the treatment of metastatic prostate cancer with Radium-223 were assessed in three papers. In conclusion, in patients undergoing RT, radiolabeled choline and [68Ga]PSMA-11 have an important prognostic role. In the case of systemic therapies, the role of such new-generation imaging techniques is still controversial without sufficient data, thus requiring additional in this scenario.

show abstract

“…After the screening, a full-text review of 30 articles was performed. According to our inclusion criteria, we finally identified 20 studies eligible for systematic review [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]. Of the twenty studies, we identified eight phase II RCTs comparing the efficacy and/or safety of ARSI-based combination therapy versus other combinations or ADT/ARSI alone (Table 1) [13][14][15][16][17][18][19][20].…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…In 2021, Chen et al conducted a pilot study assessing the performance of a 68Gaprostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/CT in the evaluation of treatment with neoadjuvant ABI + ADT for high-risk clinically localized PCa [24]. The authors showed that PET/CT changes had higher specificity in the assessment of pathologic response than PSA changes (89.7% vs. 62.1%, p = 0.043) [27].…”

Section: Radiographic Assessment Of Treatment Efficacy In Patients Tr...mentioning

confidence: 99%

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

Yanagisawa

Rajwa

Quhal

et al. 2023

JPM

View full text Add to dashboard Cite

(1) Background: Several phase II studies, including randomized controlled trials (RCTs), assessed the efficacy of adding androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) as a neoadjuvant treatment in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). Summarizing the early results of these studies could help in designing phase III trials and patient counseling. (2) Methods: We queried three databases in January 2023 for studies that included PCa patients treated with neoadjuvant ARSI-based combination therapy before RP. The outcomes of interest were oncologic outcomes and pathologic responses, such as pathologic complete response (pCR) and minimal residual disease (MRD). (3) Results: Overall, twenty studies (eight RCTs) were included in this systematic review. Compared to ADT or ARSI alone, ARSI + ADT was associated with higher pCR and MRD rates; this effect was less evident when adding a second ARSI or chemotherapy. Nevertheless, ARSI + ADT resulted in relatively low pCR rates (0–13%) with a high proportion of ypT3 (48–90%) in the resected specimen. PTEN loss, ERG positive, or intraductal carcinoma seem to be associated with worse pathologic response. One study that adjusted for the effects of possible confounders reported that neoadjuvant ARSI + ADT improved time to biochemical recurrence and metastasis-free survival compared to RP alone. (4) Conclusions: Neoadjuvant ARSI + ADT combination therapy results in improved pathologic response compared to either alone or none in patients with non-metastatic advanced PCa. Ongoing phase III RCTs with long-term oncologic outcomes, as well as biomarker-guided studies, will clarify the indication, oncologic benefits, and adverse events of ARSI + ADT in patients with clinically and biologically aggressive PCa.

show abstract

Can ⁶⁸ Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study

Cited by 11 publications

References 0 publications

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

Contact Info

Product

Resources

About

Can 68 Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study

Cited by 11 publications

References 0 publications

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects

PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

Contact Info

Product

Resources

About

Can ⁶⁸ Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study